Neurocrine Biosciences Earnings
NASDAQ: NBIXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Tue, Oct 27, 2026
Fiscal period
Sep/2026
EPS estimate
$1.99
Neurocrine Biosciences earnings summary
Neurocrine Biosciences is scheduled to report Sep/2026 earnings on Oct 27, 2026, with analysts expecting EPS of $1.99. In its most recent report on Jul 31, 2026 (Q2 2026), NBIX posted EPS of $1.39. Revenue for the quarter was $959.0 million.
Quarterly EPS is up 31.1% from the same quarter a year earlier. Across the last 16 reports, NBIX shares moved an average of 3.0% (in either direction) in the first trading session after results, rising 9 times and falling 7 times.
Summary generated from market data by MetaCap's automated system. Methodology
NBIX earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Jul 31, 2026 | — | $1.39 | — | -2.0% |
| May 5, 2026 | — | $1.91 | — | +4.1% |
| Feb 11, 2026 | — | $1.49 | — | +3.6% |
| Oct 28, 2025 | — | $2.04 | — | +6.4% |
| Jul 30, 2025 | — | $1.06 | — | -3.0% |
| May 5, 2025 | — | $0.08 | — | +4.6% |
| Feb 10, 2025 | — | $1.00 | — | +4.9% |
| Oct 30, 2024 | — | $1.24 | — | +2.9% |
| Aug 1, 2024 | — | $0.63 | — | -3.8% |
| May 1, 2024 | — | $0.42 | — | -2.8% |
| Feb 9, 2024 | — | $1.49 | — | +0.0% |
| Oct 31, 2023 | — | $0.82 | — | -4.7% |
| Aug 1, 2023 | — | $0.95 | — | +3.5% |
| May 3, 2023 | — | $-0.79 | — | -0.7% |
| Feb 9, 2023 | — | $0.91 | — | +0.3% |
| Nov 1, 2022 | — | $0.69 | — | -0.3% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.